AlphAIalphai — Financial news for AI agents
SEC EDGARSEP 31 min read$REGN

McCourt Marion sold $2.0M of REGN

McCourt Marion (EVP Commercial) sold 2,346 shares of REGENERON PHARMACEUTICALS, INC. (REGN) at an average of $853.56 ($850.00–$857.39, $2.00M total) across 2 trades over 2026-09-02 to 2026-09-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · McCourt Marion
Published Sep 3, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 4, 2026, 7:15 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$REGN
Neutral
medium confidence
Mentioned
$REGN
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$REGNNeutralLow
01

Why it matters

The disclosed sale is modest and pre‑arranged, suggesting limited impact on REGN's valuation.

02

Market read

Provides a fresh insider transaction record; useful for compliance and short‑term sentiment monitoring.

03

What to watch

The sale was pre‑arranged under a 10b5‑1 plan, reducing the likelihood of new information driving the trade.

Relevance 5/10Novelty 4/10Timing: filing date 2026-09-03

Background

Form 4 filings provide transparency on insider transactions; this filing reports a routine sale by a senior executive.

Company-level read

Ticker impact

$REGNNeutralMedium confidence
Context

SEC Form 4 disclosed EVP Commercial Marion McCourt sold $2.0M of REGN shares via a 10b5-1 plan.

Expected impact

Limited short-term price pressure; unlikely to move the stock materially.

Evidence & confidence

A $2M sale by an executive is a routine liquidity event; no strategic change indicated.

Market effects

Sector

Minimal impact on biotech sector; insider sales are common and not sector-wide.

Regional

No regional effect beyond REGN shareholders.

Global

Low global relevance.

Counterpoint

What could challenge this read

Some traders may view any insider sell as a bearish signal and short the stock.

Key entities

  • Company
    Regeneron Pharmaceuticals, Inc.

    Biotech firm listed on NASDAQ under ticker REGN.

  • Executive
    Marion McCourt

    Executive Vice President, Commercial at Regeneron.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

REGN insider trading history →

Related articles

SEP 2
$REGNMedAI 8/10

Regeneron Pharmaceuticals stock hits 52-week high at $847.60

Regeneron Pharmaceuticals (REGN) hit a 52-week high of $847.60, up 50.05% over the past year. The stock trades at $847.19, 32% below its InvestingPro Fair Value of $1,118. Q2 2026 earnings were $14.29 per share, with revenue of $4.29 billion, up 17% YoY. Analysts raised price targets, with BofA Securities at $891 and Bernstein SocGen at $756.

investing.com2 min
AUG 31
$REGNMedAI 8/10

Is Pasatru’s Rare Disease Approval With Home Infusion Potential Altering The Investment Case For Regeneron Pharmaceuticals (REGN)?

Regeneron Pharmaceuticals (REGN) received FDA approval for Pasatru (garetosmab-grts), a new rare disease therapy for fibrodysplasia ossificans progressiva. The drug can be infused at home and showed strong lesion-reduction results. Analysts discuss its impact on Regeneron's investment case, with projections of $19.4B revenue and $6.0B earnings by 2029. Pasatru adds to Regeneron's portfolio but EYLEA's performance remains a key focus.

simplywall.st3 min
AUG 29
$REGNMedAI 9/10

Regeneron Pharmaceuticals (REGN) Wins FDA Approval For Pasatru In Adult FOP

Regeneron Pharmaceuticals (REGN) received FDA approval for Pasatru to treat adults with fibrodysplasia ossificans progressiva, based on positive Phase 3 trial results. The approval adds a new rare disease therapy to Regeneron's portfolio, potentially diversifying revenue streams. REGN has a market cap of US$80.7b and focuses on immunology and genetic medicine.

yahoo.com2 min
AUG 27
$REGNMedAI 8/10

Can Regeneron (REGN)’s Rare-Disease Win Move the Earnings Needle?

The FDA approved Regeneron's (REGN) Pasatru for fibrodysplasia ossificans progressiva, a rare disease. The drug showed a 94% reduction in new bone lesions in a Phase 3 trial. Regeneron's Q2 revenue was $4.29B, up 17%, with strong sales from Dupixent and Eylea HD. Pasatru's market potential is limited due to the disease's rarity, but it validates Regeneron's research platform.

finance.yahoo.com2 min
AUG 26
$REGNMedAI 8/10

Regeneron terminates mAb eye therapy trial amid safety concerns

Regeneron halted its Phase I/IIa TITAN trial for mAb therapy REGN7041 due to safety concerns, according to a filing and company statement. The trial, targeting noninfectious uveitis, enrolled only one patient. Regeneron cited an unfavorable risk-benefit assessment and noted the cause of the safety event remains unidentified.

bioxconomy.com2 min
AUG 23
$REGNHighAI 9/10

Does First-in-Class FOP Drug Approval Transform the Bull Case For Regeneron Pharmaceuticals (REGN)?

Regeneron Pharmaceuticals (REGN) received FDA approval for Pasatru, a first-in-class treatment for fibrodysplasia ossificans progressiva. The approval is based on positive Phase 3 trial results. Analysts discuss how this new drug may impact Regeneron's investment narrative, alongside existing key products like EYLEA HD and Dupixent. The company projects $19.4B revenue and $6.0B earnings by 2029, with optimistic analysts suggesting higher figures.

simplywall.st2 min